9 METERS BIOPHARMA, INC.

2019 Q4 Form 10-K Financial Statement

#000155198621000033 Filed on March 22, 2021

View on sec.gov

Income Statement

Concept 2019 Q4 2019 2018 Q4

Balance Sheet

Concept 2019 Q4 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.590M $4.590M $5.730M
YoY Change -19.9% -19.9% 1232.56%
Cash & Equivalents $4.593M $4.590M $5.729M
Short-Term Investments
Other Short-Term Assets $640.0K $640.0K $680.0K
YoY Change -5.88% -5.88% 1260.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.223M $5.220M $6.414M
YoY Change -18.56% -18.56% 752.63%
LONG-TERM ASSETS
Property, Plant & Equipment $25.42K $70.00K $35.10K
YoY Change -27.56% 75.0% -13.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.580K $10.00K $5.580K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $73.83K $80.00K $40.68K
YoY Change 81.52% 100.0% -12.12%
TOTAL ASSETS
Total Short-Term Assets $5.223M $5.220M $6.414M
Total Long-Term Assets $73.83K $80.00K $40.68K
Total Assets $5.297M $5.300M $6.454M
YoY Change -17.93% -17.83% 708.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.890M $3.890M $3.619M
YoY Change 7.5% 7.46% 36.11%
Accrued Expenses $4.748M $4.790M $826.3K
YoY Change 474.56% 415.05% -29.99%
Deferred Revenue
YoY Change
Short-Term Debt $3.180M $3.180M $5.200M
YoY Change -38.85% -38.85% 282.35%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.91M $14.91M $10.11M
YoY Change 47.44% 47.48% -22.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $14.91M $14.91M $10.11M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $14.91M $14.91M $10.11M
YoY Change 47.44% 47.48% 281.63%
SHAREHOLDERS EQUITY
Retained Earnings -$70.56M -$43.52M
YoY Change 62.16% 124.85%
Common Stock $3.948K $2.609K
YoY Change 51.32% -78.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.614M -$9.610M -$3.659M
YoY Change
Total Liabilities & Shareholders Equity $5.297M $5.300M $6.454M
YoY Change -17.93% -17.83% 708.3%

Cashflow Statement

Concept 2019 Q4 2019 2018 Q4

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2543 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11934 USD
CY2020 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3184454 USD
CY2019 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3186997 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11934 USD
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2500000 USD
CY2019 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
574332 USD
CY2020Q4 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4042277 USD
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
23000 USD
CY2019 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
57000 USD
CY2020 nmtr Repayments Of Shortterm Convertible Debt
RepaymentsOfShorttermConvertibleDebt
2461472 USD
CY2019 nmtr Repayments Of Shortterm Convertible Debt
RepaymentsOfShorttermConvertibleDebt
7790557 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37147681 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20706919 USD
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
22560994 USD
CY2019 nmtr Warrant Inducement Expense
WarrantInducementExpense
1300000 USD
CY2019Q4 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4143269 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
136876 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30150 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5290181 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4747751 USD
CY2020 us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liability </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for derivative instruments in accordance with ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative and Hedging, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the consolidated balance sheet at fair value. The Company’s derivative financial instruments consist of embedded options in the Company’s convertible notes. The embedded derivatives include provisions that provide the noteholder with certain conversion and put rights at various conversion or redemption values as well as certain call options for the Company. See Note 6—Debt for further details.</span></div>
CY2019 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
0 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30064 USD
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2528648 USD
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6397612 USD
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1045468 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55855239 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16843958 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
33258456 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4592932 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1135968 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5728900 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37851388 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4592932 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
62912 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
874203 USD
CY2020 us-gaap Stock Issued1
StockIssued1
4643007 USD
CY2019 us-gaap Stock Issued1
StockIssued1
0 USD
CY2020 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
28754026 USD
CY2019Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
3045500 USD
CY2018Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
370000 USD
CY2019 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
CY2020 nmtr Noncash Addition Of Derivative Liability
NoncashAdditionOfDerivativeLiability
370000 USD
CY2019 nmtr Noncash Addition Of Derivative Liability
NoncashAdditionOfDerivativeLiability
1281000 USD
CY2020 nmtr Noncash Addition Of Deferred Offering Costs
NoncashAdditionOfDeferredOfferingCosts
86386 USD
CY2019 nmtr Noncash Addition Of Deferred Offering Costs
NoncashAdditionOfDeferredOfferingCosts
151137 USD
CY2020Q4 nmtr Saleof Stock Shelf Registration Maximum Equity Offering Price
SaleofStockShelfRegistrationMaximumEquityOfferingPrice
200000000 USD
CY2019Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
4181068 shares
CY2019Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.33
CY2019Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
9700000 USD
CY2019Q2 nmtr Class Of Warrant Or Right Restriction Period
ClassOfWarrantOrRightRestrictionPeriod
P45D
CY2019Q2 nmtr Class Of Warrant Or Right Purchase Price Of Each Additional Warrant
ClassOfWarrantOrRightPurchasePriceOfEachAdditionalWarrant
0.125
CY2019Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.13
CY2019Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
3897010 shares
CY2019Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2019Q2 nmtr Warrants And Rights Outstanding Exercise Commencement Period
WarrantsAndRightsOutstandingExerciseCommencementPeriod
P6M
CY2019Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.13
CY2020Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
7000 USD
CY2019Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
3045500 USD
CY2019Q4 nmtr Stock Issued During Period Shares Exerciseof Warrants
StockIssuedDuringPeriodSharesExerciseofWarrants
3593714 shares
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2600000 USD
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12230418 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.10
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.10
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1200000 USD
CY2019Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
4318272 shares
CY2019Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.025
CY2019Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7900000 USD
CY2019Q4 nmtr Class Of Warrant Or Right Number Of Shares Issued Per Warrant
ClassOfWarrantOrRightNumberOfSharesIssuedPerWarrant
1.2 shares
CY2020Q2 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
22600000 USD
CY2020Q2 nmtr Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants Net
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsNet
19200000 USD
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation of the derivative liability and warrant liabilities, valuation allowance for income tax assets, and development and management’s assessment of the Company’s ability to continue as a going concern. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to its consolidated financial statements as of and for the year ended December 31, 2020. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</span></div>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. While cash held by financial institutions may at times exceed federally insured limits, management believes that no material credit or market risk exposure exists due to the high quality of the financial institutions. The Company has not experienced any losses on such accounts.</span></div>
CY2020 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
771000 USD
CY2019 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
1347900 USD
CY2020 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
100000 USD
CY2020 nmtr Warrant Inducement Expense
WarrantInducementExpense
7200000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1111028 USD
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014 nmtr Royalties Payment Expiration Requirement
RoyaltiesPaymentExpirationRequirement
P10Y
CY2020 nmtr Accrued Milestone Fees
AccruedMilestoneFees
2200000 USD
CY2020Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
600000 shares
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
124973 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3685610 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3921424 USD
CY2020 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
488 USD
CY2019 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-101624 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19409786 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17967992 USD
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 nmtr Convertible Preferred Stock Beneficial Conversion Feature
ConvertiblePreferredStockBeneficialConversionFeature
3100000 USD
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
56368996 shares
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22822067 shares
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
12500000 USD
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2020Q2 nmtr Preferred Stock Warrant Value
PreferredStockWarrantValue
7000000.0 USD
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001551986
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
72648 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
73177 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
61457 USD
CY2020 dei City Area Code
CityAreaCode
919
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-37797
CY2020 dei Entity Registrant Name
EntityRegistrantName
9 METERS BIOPHARMA, INC.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3948465
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
8480 Honeycutt Road
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 120
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Raleigh
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27615
CY2020 dei Local Phone Number
LocalPhoneNumber
275-1933
CY2020 dei Security12b Title
Security12bTitle
Common Stock $0.0001 Par Value
CY2020 dei Trading Symbol
TradingSymbol
NMTR
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
62000000.0 USD
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
216070445 shares
CY2020Q4 us-gaap Cash
Cash
37851388 USD
CY2019Q4 us-gaap Cash
Cash
4592932 USD
CY2020Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
75000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4747751 USD
CY2019Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
75000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1000587 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
555052 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
38926975 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
5222984 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11191 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25422 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
214767 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
42830 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2020Q4 us-gaap Assets
Assets
39158513 USD
CY2019Q4 us-gaap Assets
Assets
5296816 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1487948 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3890094 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5290181 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
47755 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11191 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25422 USD
CY2020Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
14216 USD
CY2019Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
3184655 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7000 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
408000 USD
CY2020Q4 nmtr Warrant Liability Current
WarrantLiabilityCurrent
0 USD
CY2019Q4 nmtr Warrant Liability Current
WarrantLiabilityCurrent
2637500 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
488 USD
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
48629 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
42830 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6848462 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14910830 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
167938 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2020Q4 us-gaap Liabilities
Liabilities
7016400 USD
CY2019Q4 us-gaap Liabilities
Liabilities
14910830 USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
204629064 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204629064 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39477667 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39477667 shares
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
20463 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
3948 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
164182917 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60946816 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132061267 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70564778 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32142113 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-9614014 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39158513 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5296816 USD
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10933023 USD
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
13715968 USD
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
32266893 USD
CY2019 nmtr Accrued Milestone Fees
AccruedMilestoneFees
300000 USD
CY2020Q4 nmtr Capital Stock Authorized
CapitalStockAuthorized
360000000 shares
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10519955 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10566813 USD
CY2020 nmtr Warrant Inducement Expense
WarrantInducementExpense
7157887 USD
CY2019 nmtr Warrant Inducement Expense
WarrantInducementExpense
1265780 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
60877758 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
25548561 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-60877758 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-25548561 USD
CY2020 us-gaap Interest Income Other
InterestIncomeOther
18992 USD
CY2019 us-gaap Interest Income Other
InterestIncomeOther
185267 USD
CY2020 us-gaap Interest Expense
InterestExpense
4046223 USD
CY2019 us-gaap Interest Expense
InterestExpense
1825148 USD
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1049166 USD
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
771000 USD
CY2019 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1243000 USD
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2637500 USD
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
54200 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-618731 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1500247 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-61496489 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27048808 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-61496489 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-27048808 USD
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105642203 shares
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33328591 shares
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-3659064 USD
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20219756 USD
CY2019 nmtr Adjustments To Additional Paid In Capital Allocation Of Warrants To Liabilities
AdjustmentsToAdditionalPaidInCapitalAllocationOfWarrantsToLiabilities
3330000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
709442 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2871000 USD
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30064 USD
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2019 nmtr Stock Issued During Period Value Warrant Exchange
StockIssuedDuringPeriodValueWarrantExchange
2012480 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-27048808 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-9614014 USD
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37168980 USD
CY2020 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
28754026 USD
CY2020 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
22560994 USD
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2020 nmtr Stock Issued During Period Value Warrant Exchange
StockIssuedDuringPeriodValueWarrantExchange
690839 USD
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4723000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6483998 USD
CY2020 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
2528648 USD
CY2020 nmtr Adjustments To Additional Paid In Capital Warrant Inducement Expense
AdjustmentsToAdditionalPaidInCapitalWarrantInducementExpense
6467048 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
4643007 USD
CY2020 nmtr Convertible Promissory Notes Beneficial Conversion Feature
ConvertiblePromissoryNotesBeneficialConversionFeature
2200072 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-61496489 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32142113 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-61496489 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-27048808 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4723000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
2871000 USD
CY2020 nmtr Writeoff Of Deferred Offering Costs
WriteoffOfDeferredOfferingCosts
0 USD
CY2019 nmtr Writeoff Of Deferred Offering Costs
WriteoffOfDeferredOfferingCosts
100056 USD
CY2020 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
307372 USD
CY2019 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
0 USD
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1519668 USD
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1067379 USD
CY2020 us-gaap Depreciation
Depreciation
18491 USD
CY2019 us-gaap Depreciation
Depreciation
21607 USD
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-39198 USD
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2020Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.65
CY2019 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-873000 USD
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2637500 USD
CY2020 nmtr Convertible Promissory Notes Beneficial Conversion Feature
ConvertiblePromissoryNotesBeneficialConversionFeature
2200072 USD
CY2019 nmtr Convertible Promissory Notes Beneficial Conversion Feature
ConvertiblePromissoryNotesBeneficialConversionFeature
0 USD
CY2020 nmtr Asset Acquisition Research And Development In Process
AssetAcquisitionResearchAndDevelopmentInProcess
28754026 USD
CY2019 nmtr Asset Acquisition Research And Development In Process
AssetAcquisitionResearchAndDevelopmentInProcess
0 USD
CY2020 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-771000 USD
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
54200 USD
CY2020 nmtr Gain Losson Extinguishmentof Derivative Liability
GainLossonExtinguishmentofDerivativeLiability
0 USD
CY2019 nmtr Gain Losson Extinguishmentof Derivative Liability
GainLossonExtinguishmentofDerivativeLiability
370000 USD
CY2020 nmtr Warrant Inducement Expense
WarrantInducementExpense
7157887 USD
CY2019 nmtr Warrant Inducement Expense
WarrantInducementExpense
1265780 USD
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1049166 USD
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
445535 USD
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
50145 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2465074 USD
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204629064 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39477667 shares
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
25141814 shares
CY2019Q4 nmtr Class Of Warrant Or Right Number Of Shares Issued Per Warrant
ClassOfWarrantOrRightNumberOfSharesIssuedPerWarrant
1.2 shares
CY2019Q4 nmtr Stock Issued During Period Shares Exerciseof Warrants
StockIssuedDuringPeriodSharesExerciseofWarrants
3593714 shares
CY2020 nmtr Stock Issued During Period Shares Exerciseof Warrants
StockIssuedDuringPeriodSharesExerciseofWarrants
1847309 shares
CY2020Q2 nmtr Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
12230418 shares
CY2020Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1200000 USD
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
66167171 shares
CY2020Q4 nmtr Number Of Stock Option Plans
NumberOfStockOptionPlans
2 plan
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2805700 USD
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3139400 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1358200 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
723800 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3864900 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4723000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2871000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13798700 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9857000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
4587100 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1716300 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
6900 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
88500 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
122500 USD
CY2020Q4 nmtr Deferred Tax Assets Legal Fees
DeferredTaxAssetsLegalFees
40200 USD
CY2019Q4 nmtr Deferred Tax Assets Legal Fees
DeferredTaxAssetsLegalFees
111800 USD
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
204800 USD
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
60100 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27088700 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15397200 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11691500 USD
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6624200 USD
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-12914300 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5680200 USD
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-661300 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.011
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-534200 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.020
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
1337100 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.022
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
89100 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.003
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-6425000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.104
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0
CY2020 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
634400 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.010
CY2019 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
540200 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.020
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-562600 USD
CY2020 nmtr Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Amount
EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalAmount
-1400 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
56544400 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.009
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
0 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0
CY2020 nmtr Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Percent
EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalPercent
0
CY2019 nmtr Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Amount
EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalAmount
0 USD
CY2019 nmtr Effective Income Tax Rate Reconciliation Changein Enacted Tax Rate Stateand Local Percent
EffectiveIncomeTaxRateReconciliationChangeinEnactedTaxRateStateandLocalPercent
0
CY2020 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
107400 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.001
CY2019 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
41300 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.002
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6904500 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.113
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6624200 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.245
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
3551900 USD
CY2017Q4 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
5000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
10300 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1358200 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2020 nmtr Severance Provisions Annual Base Salary Period
SeveranceProvisionsAnnualBaseSalaryPeriod
P12M
CY2020 nmtr Severance Provisions Continuation Of Health Insurance Benefits Period
SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod
P12M
CY2020 us-gaap Severance Costs1
SeveranceCosts1
800000 USD
CY2019 us-gaap Severance Costs1
SeveranceCosts1
300000 USD
CY2020 nmtr Severance Costs Equal Installment Period
SeveranceCostsEqualInstallmentPeriod
P12M
CY2020Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
300000 USD
CY2017Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2017Q4 nmtr Operating Lease Annual Rental Payments
OperatingLeaseAnnualRentalPayments
60000 USD
CY2017Q4 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
5000 USD
CY2017Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P24M
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
5000 USD
CY2017Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 nmtr Operating Lease Annual Rental Payments
OperatingLeaseAnnualRentalPayments
72000 USD
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 USD
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 USD
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233206 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
233206 USD
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
64800 USD
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
60000 USD
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
100000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
72000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
72000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
72000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
54000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
270000 USD
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
53433 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
216567 USD

Files In Submission

Name View Source Status
0001551986-21-000033-index-headers.html Edgar Link pending
0001551986-21-000033-index.html Edgar Link pending
0001551986-21-000033.txt Edgar Link pending
0001551986-21-000033-xbrl.zip Edgar Link pending
ex-211listofsubsidiaries.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nmtr-20201231.htm Edgar Link pending
nmtr-20201231.xsd Edgar Link pending
nmtr-20201231_cal.xml Edgar Link unprocessable
nmtr-20201231_def.xml Edgar Link unprocessable
nmtr-20201231_g1.jpg Edgar Link pending
nmtr-20201231_g10.jpg Edgar Link pending
nmtr-20201231_g11.jpg Edgar Link pending
nmtr-20201231_g12.jpg Edgar Link pending
nmtr-20201231_g13.jpg Edgar Link pending
nmtr-20201231_g2.jpg Edgar Link pending
nmtr-20201231_g3.jpg Edgar Link pending
nmtr-20201231_g4.jpg Edgar Link pending
nmtr-20201231_g5.jpg Edgar Link pending
nmtr-20201231_g6.jpg Edgar Link pending
nmtr-20201231_g7.jpg Edgar Link pending
nmtr-20201231_g8.jpg Edgar Link pending
nmtr-20201231_g9.jpg Edgar Link pending
nmtr-20201231_htm.xml Edgar Link completed
nmtr-20201231_lab.xml Edgar Link unprocessable
nmtr-20201231_pre.xml Edgar Link unprocessable
nmtrex-3112020.htm Edgar Link pending
nmtrex23-12020consent.htm Edgar Link pending
nmtrex31-22020.htm Edgar Link pending
nmtrex32-12020.htm Edgar Link pending
nmtrex32-22020.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending